ALNYLAM PHARMACEUTICALS, INC.
For the period ended Sep 30, 2026. Filed Oct 29, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 29, 2026
ALNY$155.94-0.5%Stored close · as of Nov 6, 2026
Contents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net income | $2,537,820 | $202,204 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Depreciation and amortization | 41,928 | 42,152 |
| Non-cash interest expense on liabilities related to the sale of future royalties and development funding | 226,646 | 176,235 |
| Stock-based compensation expense | 235,897 | 276,603 |
| Realized and unrealized loss on marketable equity securities | — | 2,306 |
| Loss on extinguishment of debt | — | 39,146 |
| Deferred income taxes | (1,882,763) | 24,972 |
| Other | 7,845 | (31,464) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (313,300) | (544,210) |
| Inventory | (2,131) | 22,335 |
| Prepaid expenses and other assets | (102,099) | (46,734) |
| Accounts payable, accrued expenses and other liabilities | (18,454) | 195,745 |
| Deferred revenue | 6,824 | (52,940) |
| Net cash provided by operating activities | 738,213 | 306,350 |
| Cash flows from investing activities: | ||
| Purchases of property, plant and equipment | (126,345) | (35,405) |
| Purchases of marketable securities | (1,346,894) | (1,069,170) |
| Sales and maturities of marketable securities | 753,177 | 1,580,220 |
| Proceeds from maturity of restricted and other investments | 68,425 | 59,775 |
| Purchases of restricted and other investments | (22,000) | (59,775) |
| Other investing activities | (27,100) | (2,150) |
| Net cash (used in) provided by investing activities | (700,737) | 473,495 |
| Cash flows from financing activities: | ||
| Proceeds from issuance of 0.00% Convertible Senior Notes due 2028, net | — | 646,372 |
| Purchases of capped calls related to 0.00% Convertible Senior Notes due 2028 | — | (35,311) |
| Repayment of 1.00% Convertible Senior Notes due 2027 | — | (1,102,659) |
| Payment of issuance costs for revolving credit agreement | — | (2,414) |
| Proceeds from exercise of stock options and other types of equity, net | 62,183 | 208,327 |
| Proceeds from liabilities related to the sale of future royalties and development funding | 18,000 | — |
| Repayment of liabilities related to the sale of future royalties and development funding | (9,865) | (10,647) |
| Other financing activities | (16) | — |
| Net cash provided by (used in) financing activities | 70,302 | (296,332) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (10,768) | 40,637 |
| Net increase in cash, cash equivalents and restricted cash | 97,010 | 524,150 |
| Cash, cash equivalents and restricted cash, beginning of period | 1,658,807 | 968,652 |
| Cash, cash equivalents and restricted cash, end of period | $1,755,817 | $1,492,802 |
| Supplemental disclosure of cash flows: | ||
| Cash paid for interest | $195,565 | $159,565 |
| Cash paid for taxes | $29,810 | $2,375 |
| Operating lease right-of-use assets obtained in exchange for new operating lease liabilities | $457 | $12,379 |
| Supplemental disclosure of noncash investing activities: | ||
| Capital expenditures included in accounts payable and accrued expenses | $29,227 | $9,604 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.